Pharmaceuticals, Biotechnology and Life Sciences
Arix Bioscience’s issued ordinary shares have on Wednesday been admitted to the Official List of the UK Listing Authority and to trading on the London Stock Exchange’s main market for listed securities under the ticker “ARIX”.
Advanced Oncotherapy, the developer of next generation proton therapy systems for cancer treatment, has secured a flexible and staged £26 million financing agreement with Bracknor Investment Group, a Dubai-based investment firm.
What does a healthy heart really mean? Is it just the physical heart muscle that matters, or is there an important emotional component?
And can the simple act of conveying your best wishes and intentions make a real difference in the health of the recipient’s heart — and even your own? What does the science say?
Players in the Global Pharmacy Repackaging Systems Market are facing tough competition. Despite tough grounds, the players such as Omnicell Inc. and Swisslog Holding AG are leading with a share of about 34% in the global market in 2015.
Bristol-Myers Squibb has entered into an ASR program with each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock, and it has named three new directors.
Amgen on Tuesday got clearance from the European Commission (EC) for a new single-dose delivery option for its Repatha cardiovascular drug.
Following a diet that mimics fasting may reduce risk factors for disease in generally healthy people, according to a small study.
Studies drug companies fund after medicines go on sale may be too small to detect rare side effects, a recent German study suggests.
Omnicell has bagged a deal with Inova, a not-for-profit healthcare system based in Northern Virginia, for its integrated software and services offering, Performance Center.
The American Brain Tumor Association (ABTA) has elected four new members to its Board of Directors in January, to bring the number of directors to thirteen.